Next Financial Statements From 2010 to 2025
| NXSCF Stock | USD 0.06 0.02 28.75% |
Check Next Science financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Next Science's main balance sheet or income statement drivers, such as , as well as many indicators such as . Next financial statements analysis is a perfect complement when working with Next Science Valuation or Volatility modules.
Next |
Next Science Limited Company Return On Equity Analysis
Next Science's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Next Science Return On Equity | -0.77 |
Most of Next Science's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Next Science Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Next Science Limited has a Return On Equity of -0.7736. This is 96.77% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—Specialty & Generic industry. The return on equity for all United States stocks is 149.55% higher than that of the company.
Next Science Limited Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Next Science's current stock value. Our valuation model uses many indicators to compare Next Science value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Next Science competition to find correlations between indicators driving Next Science's intrinsic value. More Info.Next Science Limited is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Next Science's earnings, one of the primary drivers of an investment's value.About Next Science Financial Statements
Next Science stakeholders use historical fundamental indicators, such as Next Science's revenue or net income, to determine how well the company is positioned to perform in the future. Although Next Science investors may analyze each financial statement separately, they are all interrelated. For example, changes in Next Science's assets and liabilities are reflected in the revenues and expenses on Next Science's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Next Science Limited. Please read more on our technical analysis and fundamental analysis pages.
Next Science Limited, a medical technology company, researches, develops, and commercializes technologies that address the impacts of biofilms in human health in the United States and Australia. Next Science Limited was founded in 2012 and is headquartered in Chatswood, Australia. Next Science operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Next Pink Sheet
Next Science financial ratios help investors to determine whether Next Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Next with respect to the benefits of owning Next Science security.